MOTS-c (Mitochondrial Open reading frame of the twelve S rRNA-c) is a 16-amino-acid peptide encoded within the mitochondrial genome — specifically within the 12S ribosomal RNA gene — making it one of only a handful of known bioactive peptides with a mitochondrial rather than nuclear genetic origin. It was first described in a landmark 2015 paper by Changhan David Lee and colleagues at the University of Southern California, published in Cell Metabolism. The discovery represented a conceptual shift: mitochondria had previously been understood primarily as energy-producing organelles, not as endocrine signalling centres producing bioactive peptides that regulate whole-body metabolism.
Key Takeaways
- —MOTS-c is a 16-aa peptide encoded in the mitochondrial 12S rRNA gene — not the nuclear genome — making it one of only a few known mitochondria-derived bioactive peptides (Lee et al., Cell Metabolism, 2015).
- —Intraperitoneal injection of MOTS-c in high-fat diet mice reduced diet-induced obesity by 40% and improved insulin sensitivity, with effects attributed to AMPK activation in skeletal muscle.
- —MOTS-c translocates to the nucleus in response to metabolic stress, binding AMPK and upregulating genes involved in glucose uptake, fatty acid oxidation, and mitochondrial biogenesis.
- —Circulating MOTS-c levels in humans decline significantly with age, with levels in 50–65 year-olds approximately 40–60% lower than in 20–30 year-olds — suggesting a potential role in age-related metabolic decline.
The discovery of MOTS-c challenged the longstanding model of mitochondria as passive energy factories. Mitochondria are endosymbiotic bacteria that became integrated into eukaryotic cells approximately 2 billion years ago. They retain their own circular genome, which encodes 37 genes in humans — 13 protein-coding, 22 tRNAs, and 2 rRNAs. MOTS-c is encoded within one of those rRNA genes (12S rRNA), in a region not previously recognised as protein-coding.
Lee's team used computational genomics to identify the open reading frame encoding MOTS-c within 12S rRNA, synthesised the corresponding peptide, and showed it was expressed endogenously in multiple tissues including liver, skeletal muscle, and plasma. MOTS-c circulates in the blood, meaning it functions as a hormone — communicating mitochondrial metabolic status to distant tissues.
The mitochondrial genetic origin of MOTS-c is not merely an interesting curiosity — it's functionally relevant. Because mitochondria replicate independently of nuclear DNA and accumulate mutations at approximately 10× the rate of nuclear DNA, MOTS-c levels vary by mitochondrial haplotype. Published data shows that individuals with certain mitochondrial haplogroups associated with longevity (e.g., haplogroup D4 in Japanese centenarian studies) have higher MOTS-c expression. This connects MOTS-c to the genetics of exceptional longevity in a way no nuclear-encoded peptide can claim.
AMPK activation: The primary downstream effector of MOTS-c is AMP-activated protein kinase (AMPK), the master energy sensor of eukaryotic cells. AMPK is activated when cellular AMP/ATP ratio rises (i.e., when energy is low), triggering metabolic programmes that increase energy production (fatty acid oxidation, glucose uptake) and decrease energy consumption (lipid synthesis, gluconeogenesis). MOTS-c activates AMPK — particularly in skeletal muscle — without requiring the actual energy-depletion trigger, effectively mimicking the metabolic signal of exercise.
Nuclear translocation under stress: In metabolic stress conditions, MOTS-c translocates from the cytoplasm to the nucleus, where it directly binds and activates the AMPK promoter and interacts with ARE (antioxidant response element) binding proteins. This nuclear role — a peptide acting as a transcriptional modulator — is mechanistically unusual for a circulating hormone.
AICAR pathway convergence: MOTS-c inhibits the folate cycle in the one-carbon metabolic pathway, leading to accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), a well-established endogenous AMPK activator. This creates a second, indirect AMPK activation route.
Glucose and fatty acid metabolism: MOTS-c treatment increases GLUT4 translocation to the plasma membrane (enhancing glucose uptake) and upregulates CPT1 and other genes governing mitochondrial fatty acid oxidation — the combined effect being improved metabolic flexibility.
The Kim/Lee 2015 Cell Metabolism paper remains the foundational study. Key findings:
Subsequent studies (2016–2023) extended these findings:
Human dosing protocols for MOTS-c are extrapolated from mouse data (allometric scaling) and early clinical use, not from published human RCTs. The Lee 2015 mouse protocol used 0.5 mg/kg/day intraperitoneally. Allometric scaling to humans (using the standard 12:1 mouse-to-human conversion) suggests an equivalent human dose in the range of 2–5 mg/day.
| Parameter | Research Protocol Range |
|---|---|
| Dose | 5–10 mg per injection |
| Route | Subcutaneous |
| Frequency | 1–3× per week |
| Cycle | 4–8 weeks on, 4 weeks off |
| Reconstitution | Bacteriostatic water (standard) |
The absence of published human pharmacokinetic data means these protocols are provisional. The half-life of MOTS-c in plasma is not well characterised in humans. Practitioners often start at the lower end (5 mg 2× weekly) and assess response via subjective energy/performance metrics and, where possible, metabolic markers (fasting glucose, HbA1c).
MOTS-c is an endogenous human peptide — encoded in the mitochondrial genome and produced naturally in skeletal muscle, liver, and other tissues. This endogenous status provides a meaningful baseline safety argument: the compound exists in the human body normally, and what's being administered exogenously is more of a supplement to declining endogenous production than an introduction of a foreign agent.
Published adverse event data from animal studies reports no toxicity at therapeutic doses. Human adverse event data is limited to case reports and small clinical series — no systematic safety study has been published. Injection site reactions are the primary reported issue.
MOTS-c is one of the most scientifically novel compounds in the research peptide space — and one of the most commonly misrepresented on vendor sites. The Next Pep peptide library covers the full 16-aa mitochondrially-encoded peptide profile: AMPK activation mechanism, the Lee et al. 2015 Cell Metabolism HFD mouse data, the age-related decline curve, and the insulin sensitivity and sarcopenia evidence — all against primary sources, not marketing copy.
Use the comparison tool to put MOTS-c alongside other metabolic or longevity peptides side-by-side — mechanism, evidence quality, and access route compared in one view. The dosing calculator handles reconstitution for SC protocols: enter your vial concentration and it returns exact draw volume and syringe units. Research the compound on Next Pep before evaluating any supplier.
Most exercise mimetics (AICAR, GW501516) are small molecules targeting specific pathways. MOTS-c is an endogenous peptide that activates AMPK through a biologically natural route — it's the signal the body normally uses to communicate mitochondrial metabolic status. Additionally, its mitochondrial genetic origin connects it to genuine longevity genetics in ways small-molecule mimetics cannot.
No — the "exercise mimetic" label reflects mechanistic overlap at the molecular level (AMPK activation, GLUT4 upregulation, mitochondrial biogenesis genes), not a complete replication of exercise's benefits. Exercise produces mechanical loading effects, cardiovascular adaptations, and hormonal responses that MOTS-c cannot replicate. The realistic use case is enhancing metabolic efficiency and insulin sensitivity — particularly in older individuals or those with metabolic dysfunction.
Endogenous MOTS-c levels decline with age — published data shows levels in 50–65 year-olds are 40–60% lower than in young adults. This decline parallels the development of age-related insulin resistance, sarcopenia, and reduced mitochondrial biogenesis. The hypothesis that restoring MOTS-c levels reverses some of these metabolic age effects is mechanistically plausible and supported by animal data, but human intervention data is not yet available.
Both are mitochondria-derived peptides (MDPs) encoded in the 12S rRNA gene. Humanin was the first MDP discovered (2003), and its primary characterised effects are neuroprotection (inhibiting amyloid beta toxicity) and cytoprotection. MOTS-c is primarily metabolic — AMPK activation, insulin sensitisation, mitochondrial biogenesis. They function in overlapping but distinct pathways and are sometimes used together in longevity-focused protocols.
This article is for research and educational purposes only. MOTS-c is not FDA-approved for any therapeutic use. Consult a licensed healthcare professional before considering any peptide protocol.
Research Disclaimer. All content on Next Pep is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a licensed healthcare professional before considering any peptide protocol.
A head-to-head comparison of BPC-157 and TB-500 covering mechanism, tissue specificity, dosing frequency, human evidence, and whether stacking them adds anything the literature actually supports.
Ipamorelin is a ghrelin-receptor agonist; CJC-1295 is a GHRH analog. Their mechanisms are complementary, which is why protocols typically stack them. This guide covers what each does alone, what stacking adds, and the DAC vs non-DAC distinction.